

[Symposium 13-4]

Current Status and Challenges of Peritoneal Dialysis Therapy in Taiwan

Chih-Yu Yang

Division of Nephrology, Taipei Veterans General Hospital, Taiwan

Despite Taiwan having an impressive 5-year cumulative survival rate for peritoneal dialysis (PD) patients and a declining incidence of PD peritonitis, the utilization of PD has continued to decline, with its prevalence dropping from 9.6% in 2011 to 7.5% in 2021, falling behind regions such as Hong Kong (68%) and Norway (22%). To address this trend and enhance PD as a dialysis modality, Taiwan's National Health Insurance Administration launched a reimbursement initiative in July 2023. This initiative aims to improve the quality of PD care, encourage the establishment of new PD units, enhance staff training, and promote integrative care through collaborative networks between medical centers and community clinics. Notably, this initiative emphasizes comprehensive shared decision-making on dialysis modality selection and includes reimbursement for telemedicine video consultations.

As of the end of 2023, the initiative's success is evident in the reopening of six previously closed PD units, the establishment of 68 new units, and an increase in the PD crude prevalence rate from 7.5% to 7.9%. Adherence to high-quality PD care standards has also improved, with medical centers achieving a 100% adherence rate and regional hospitals reaching nearly 90%. This ongoing program, which is set to continue for at least three years, not only aims to halt the decline in PD utilization but also seeks to enhance the quality of life for patients requiring kidney replacement therapy. We look forward to sharing the long-term outcomes and insights gained through this initiative in future studies.

Meanwhile, the PD Working Committee of the Taiwan Society of Nephrology is collaborating with the National Health Research Institute to elucidate the incidence of encapsulating peritoneal sclerosis (EPS) in Taiwan. This task aims to establish a consensus on the diagnosis and management of EPS to guide young nephrologists, as well as to optimize the timely transition from PD to hemodialysis therapy for patients receiving PD.

